Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07816640 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Renal Oxygenation-Guided AKI Reduction Trial

Study acronym: ROGAR
StatusNot Yet Recruiting
PhaseNot applicable
Started2026-09-20
View on ClinicalTrials.gov ↗
Acute kidney injury (AKI) is a common complication after major liver surgery. This study will evaluate whether intraoperative management guided by renal regional oxygen saturation (RrSO₂), measured using near-infrared spectroscopy, can reduce postoperative acute kidney injury in adults undergoing elective hepatectomy. Approximately 1,200 participants at about 20 hospitals in China will be randomly assigned in a 1:1 ratio to RrSO₂-guided management or usual perioperative care. All participants will undergo continuous bilateral renal RrSO₂ monitoring. In the intervention group, RrSO₂ values will be visible to the anesthesia team, and a decrease of 10% or more from baseline on either side will trigger a standardized assessment and stepwise management algorithm. In the control group, RrSO₂ data will be recorded but concealed from the clinical team and will not guide treatment. The primary outcome is AKI within 7 days after surgery or before hospital discharge, whichever occurs first, based on Kidney Disease: Improving Global Outcomes serum creatinine criteria or initiation of renal replacement therapy.
Trial Details
NCT Number NCT07816640
Lead Sponsor Chinese PLA General Hospital
Conditions Acute Kidney Injury, Hepatectomy
Enrollment 1,200 participants
Start Date 2026-09-20
Primary Completion 2027-11-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-14